NFκB activation by modified vaccinia virus as a novel strategy to enhance neutrophil migration and HIV-specific T-cell responses

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 11, 2015, Pages E1333-E1342

  Pilato, Mauro Di ^a   Mejías Pérez, Ernesto ^a   Zonca, Manuela ^a   Perdiguero, Beatriz ^a   Gómez, Carmen Elena ^a   Trakala, Marianna ^b   Nieto, Jacobo ^a   Nájera, José Luis ^a   Sorzano, Carlos Oscar S ^a   Combadière, Christophe ^c   Pantaleo, Giuseppe ^d   Planelles, Lourdes ^a   Esteban, Mariano ^a  

^a CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^b Structural Biology and Biocomputing Programme   (Spain)

^c INSERM   (France)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

HIV; Neutrophils; NF B; Vaccine; Vaccinia virus

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; VACCINIA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN;

ANIMAL EXPERIMENT; ANTIGEN PRESENTING CELL; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE C; IMMUNE RESPONSE; LEUKOCYTE MIGRATION; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; ANIMAL; BAGG ALBINO MOUSE; BIOLOGICAL MODEL; C57BL MOUSE; CELL LINE; GENE DELETION; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; IMMUNOPATHOLOGY; LEUKOCYTE DISORDER; LYMPHOCYTE ACTIVATION; METABOLISM; NEUTROPHIL CHEMOTAXIS; SPECIES DIFFERENCE; VACCINIA; VACCINIA VIRUS; VIROLOGY; VIRUS GENE;

HUMAN IMMUNODEFICIENCY VIRUS 1; MUS; POXVIRIDAE; VACCINIA VIRUS;

ANIMALS; ANTIGEN-PRESENTING CELLS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; GENE DELETION; GENES, VIRAL; HIV ANTIGENS; HIV-1; HUMANS; IMMUNE SYSTEM DISEASES; LEUKOCYTE DISORDERS; LYMPHOCYTE ACTIVATION; MICE, INBRED BALB C; MICE, INBRED C57BL; MODELS, BIOLOGICAL; NEUTROPHIL INFILTRATION; NF-KAPPA B; SPECIES SPECIFICITY; VACCINIA; VACCINIA VIRUS;

EID: 84925281991     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1424341112     Document Type: Article

References (53)

1. Gómez CE, Nájera JL, Krupa M, Perdiguero B, Esteban M (2011) MVA and NYVAC as vaccines against emergent infectious diseases and cancer. Curr Gene Ther 11(3): 189-217.
2. Smith GL, et al. (2013) Vaccinia virus immune evasion: Mechanisms, virulence and immunogenicity. J Gen Virol 94(Pt 11):2367-2392.
3. Nathan C (2006) Neutrophils and immunity: Challenges and opportunities. Nat Rev Immunol 6(3):173-182.
4. Sørensen OE, et al. (2001) Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood 97(12): 3951-3959.
5. Hashimoto Y, Moki T, Takizawa T, Shiratsuchi A, Nakanishi Y (2007) Evidence for phagocytosis of influenza virus-infected, apoptotic cells by neutrophils and macrophages in mice. J Immunol 178(4):2448-2457.
6. Borregaard N (2010) Neutrophils, from marrow to microbes. Immunity 33(5):657-670.
7. Brinkmann V, et al. (2004) Neutrophil extracellular traps kill bacteria. Science 303(5663):1532-1535.
8. Chtanova T, et al. (2008) Dynamics of neutrophil migration in lymph nodes during infection. Immunity 29(3):487-496.
9. Beauvillain C, et al. (2007) Neutrophils efficiently cross-prime naive T cells in vivo. Blood 110(8):2965-2973.
10. Matsushima H, et al. (2013) Neutrophil differentiation into a unique hybrid population exhibiting dual phenotype and functionality of neutrophils and dendritic cells. Blood 121(10):1677-1689.
11. Oehler L, et al. (1998) Neutrophil granulocyte-committed cells can be driven to acquire dendritic cell characteristics. J Exp Med 187(7):1019-1028.
12. Fanger NA, et al. (1997) Activation of human T cells by major histocompatability complex class II expressing neutrophils: Proliferation in the presence of superantigen, but not tetanus toxoid. Blood 89(11):4128-4135.
13. Duffy D, et al. (2012) Neutrophils transport antigen from the dermis to the bone marrow, initiating a source of memory CD8+ T cells. Immunity 37(5):917-929.
14. Akira S, Uematsu S, Takeuchi O (2006) Pathogen recognition and innate immunity. Cell 124(4):783-801.
15. Jin MS, Lee JO (2008) Structures of the toll-like receptor family and its ligand complexes. Immunity 29(2):182-191.
16. Delaloye J, et al. (2009) Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome. PLoS Pathog 5(6):e1000480.
17. Hutchens MA, et al. (2008) Protective effect of Toll-like receptor 4 in pulmonary vaccinia infection. PLoS Pathog 4(9):e1000153.
18. Bowie A, et al. (2000) A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling. Proc Natl Acad Sci USA 97(18):10162-10167.
19. Mansur DS, et al. (2013) Poxvirus targeting of E3 ligase β-TrCP by molecular mimicry: A mechanism to inhibit NF-κB activation and promote immune evasion and virulence. PLoS Pathog 9(2):e1003183.
20. Chen RA, Ryzhakov G, Cooray S, Randow F, Smith GL (2008) Inhibition of IkappaB kinase by vaccinia virus virulence factor B14. PLoS Pathog 4(2):e22.
21. Ember SW, Ren H, Ferguson BJ, Smith GL (2012) Vaccinia virus protein C4 inhibits NF-κB activation and promotes virus virulence. J Gen Virol 93(Pt 10):2098-2108.
22. Myskiw C, Arsenio J, van Bruggen R, Deschambault Y, Cao J (2009) Vaccinia virus E3 suppresses expression of diverse cytokines through inhibition of the PKR, NF-kappaB, and IRF3 pathways. J Virol 83(13):6757-6768.
23. Shisler JL, Jin XL (2004) The vaccinia virus K1L gene product inhibits host NF-kappaB activation by preventing IkappaBalpha degradation. J Virol 78(7):3553-3560.
24. Schröder M, Baran M, Bowie AG (2008) Viral targeting of DEAD box protein 3 reveals its role in TBK1/IKKepsilon-mediated IRF activation. EMBO J 27(15):2147-2157.
25. Gedey R, Jin XL, Hinthong O, Shisler JL (2006) Poxviral regulation of the host NFkappaB response: The vaccinia virus M2L protein inhibits induction of NF-kappaB activation via an ERK2 pathway in virus-infected human embryonic kidney cells. J Virol 80(17):8676-8685.
26. Maluquer de Motes C, et al. (2011) Inhibition of apoptosis and NF-κB activation by vaccinia protein N1 occur via distinct binding surfaces and make different contributions to virulence. PLoS Pathog 7(12):e1002430.
27. Gómez CE, et al. (2007) Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C. Vaccine 25(11):1969-1992.
28. Shin HM, et al. (2004) Inhibitory action of novel aromatic diamine compound on lipopolysaccharide-induced nuclear translocation of NF-kappaB without affecting IkappaB degradation. FEBS Lett 571(1-3):50-54.
29. Wild J, et al. (2009) Preclinical evaluation of the immunogenicity of C-type HIV-1-based DNA and NYVAC vaccines in the Balb/C mouse model. Viral Immunol 22(5): 309-319.
30. Daley JM, Thomay AA, Connolly MD, Reichner JS, Albina JE (2008) Use of Ly6G-specific monoclonal antibody to deplete neutrophils in mice. J Leukoc Biol 83(1):64-70.
31. Graham SC, et al. (2008) Vaccinia virus proteins A52 and B14 share a Bcl-2-like fold but have evolved to inhibit NF-kappaB rather than apoptosis. PLoS Pathog 4(8):e1000128.
32. Kalverda AP, et al. (2009) Poxvirus K7 protein adopts a Bcl-2 fold: Biochemical mapping of its interactions with human DEAD box RNA helicase DDX3. J Mol Biol 385(3): 843-853.
33. Harte MT, et al. (2003) The poxvirus protein A52R targets Toll-like receptor signaling complexes to suppress host defense. J Exp Med 197(3):343-351.
34. Araki H, et al. (2004) Reprogramming of human postmitotic neutrophils into macrophages by growth factors. Blood 103(8):2973-2980.
35. Fridlender ZG, et al. (2009) Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell 16(3):183-194.
36. Lehmann MH, et al. (2009) Modified vaccinia virus Ankara triggers chemotaxis of monocytes and early respiratory immigration of leukocytes by induction of CCL2 expression. J Virol 83(6):2540-2552.
37. Abadie V, et al. (2009) Original encounter with antigen determines antigen-presenting cell imprinting of the quality of the immune response in mice. PLoS ONE 4(12):e8159.
38. Gómez CE, Perdiguero B, Garcia-Arriaza J, Esteban M (2012) Poxvirus vectors as HIV/AIDS vaccines in humans. Hum Vaccin Immunother 8(9):1192-1207.
39. Barouch DH, et al. (2013) Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell 155(3):531-539.
40. Rerks-Ngarm S, et al.; MOPH-TAVEG Investigators (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361(23):2209-2220.
41. Goulder PJ, Watkins DI (2008) Impact of MHC class I diversity on immune control of immunodeficiency virus replication. Nat Rev Immunol 8(8):619-630.
42. Yang OO, Daar ES, Ng HL, Shih R, Jamieson BD (2011) Increasing CTL targeting of conserved sequences during early HIV-1 infection is correlated to decreasing viremia. AIDS Res Hum Retroviruses 27(4):391-398.
43. Kiepiela P, et al. (2007) CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 13(1):46-53.
44. Iwamoto N, et al. (2014) Control of simian immunodeficiency virus replication by vaccine-induced Gag- and Vif-specific CD8+ T cells. J Virol 88(1):425-433.
45. Betts MR, et al. (2006) HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107(12):4781-4789.
46. Harari A, et al. (2008) An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med 205(1): 63-77.
47. Yang CW, Strong BS, Miller MJ, Unanue ER (2010) Neutrophils influence the level of antigen presentation during the immune response to protein antigens in adjuvants. J Immunol 185(5):2927-2934.
48. Perdiguero B, et al. (2013) Deletion of the vaccinia virus gene A46R, encoding for an inhibitor of TLR signalling, is an effective approach to enhance the immunogenicity in mice of the HIV/AIDS vaccine candidate NYVAC-C. PLoS ONE 8(9):e74831.
49. Di Pilato M, et al. (2013) New vaccinia virus promoter as a potential candidate for future vaccines. J Gen Virol 94(Pt 12):2771-2776.
50. Nájera JL, Gómez CE, García-Arriaza J, Sorzano CO, Esteban M (2010) Insertion of vaccinia virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens. PLoS ONE 5(6):e11406.
51. Ramírez JC, Gherardi MM, Esteban M (2000) Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: Virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine. J Virol 74(2):923-933.
52. Kibler KV, et al. (2011) Improved NYVAC-based vaccine vectors. PLoS ONE 6(11): e25674.
53. Gómez CE, et al. (2007) Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B. Vaccine 25(15):2863-2885.